# reload+after+2024-01-22 18:45:48.894740
address1§20 Eastbourne Terrace
city§London
zip§W2 6LG
country§United Kingdom
phone§44 20 3325 0660
website§https://www.livanova.com
industry§Medical Devices
sector§Healthcare
longBusinessSummary§LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. It also engages in research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
fullTimeEmployees§2900
companyOfficers§[{'maxAge': 1, 'name': 'Mr. William A. Kozy', 'age': 71, 'title': 'Chairman of Board & Interim CEO', 'yearBorn': 1952, 'fiscalYear': 2022, 'totalPay': 185000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alex  Shvartsburg', 'age': 52, 'title': 'Chief Financial Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 852198, 'exercisedValue': 0, 'unexercisedValue': 46910}, {'maxAge': 1, 'name': 'Ms. Trui  Hebbelinck', 'age': 51, 'title': 'Chief Human Resources Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 731407, 'exercisedValue': 0, 'unexercisedValue': 75184}, {'maxAge': 1, 'name': 'Lindsey  Little', 'title': 'Senior Director of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael  Hutchinson', 'age': 52, 'title': 'Senior VP, Chief Legal Officer & Company Secretary', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Deanna  Wilke', 'title': 'Vice President of Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Matthew Joseph Dodds III', 'title': 'Senior Vice President of Corporate Development & IT', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Bryan D. Olin Ph.D.', 'age': 56, 'title': 'Senior VP & Head of Product Development - Neuromodulation', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ryan  Miller', 'title': 'President of Advanced Circulatory Support', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Stephanie  Bolton', 'title': 'President of Global Epilepsy', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§3
compensationRisk§4
shareHolderRightsRisk§3
overallRisk§3
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.847
priceToSalesTrailing12Months§2.3508232
currency§USD
dateShortInterest§1702598400
forwardEps§3.01
pegRatio§-4.0
exchange§NMS
quoteType§EQUITY
shortName§LivaNova PLC
longName§LivaNova PLC
firstTradeDateEpochUtc§1445261400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§061a8c8c-b203-3fe1-ac5c-dcaa64a141fe
gmtOffSetMilliseconds§-18000000
targetHighPrice§82.0
targetLowPrice§47.0
targetMeanPrice§61.22
targetMedianPrice§58.0
recommendationMean§2.1
recommendationKey§buy
numberOfAnalystOpinions§9
quickRatio§1.435
grossMargins§0.67433
ebitdaMargins§0.10107
trailingPegRatio§38.6841
